AHIP Letter Concerning National Coverage Determination Analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
posted by AHIP
on August 11, 2021
Alzheimer’s disease takes a heavy toll on patients, their caregivers, and their family members. They need and deserve access to Food and Drug Administration (FDA) approved treatments that are safe, effective, and equitable for this irreversible, progressive, and debilitating disease. As the national association whose members provide health care coverage, services, and solutions to hundreds of millions of Americans every day, AHIP1 supports access to treatments that improve a patient’s quality of life and ability to enjoy more valued time with loved ones.